2017/08/03 by Tetsuya Tsukamoto, Mitsuru Nakagawa, Yuka Kiriyama +2 · 1 citation
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastric Cancer Management and Outcomes #Eosinophilic Esophagitis #Helicobacter pylori #Intestinal metaplasia #Cancer #Atrophic gastritis #Gastroenterology #Dysplasia #Medicine #Internal medicine #Adenocarcinoma #Stomach #Cancer prevention #Incidence (geometry) #Stomach cancer #Gastritis #Chronic gastritis
paper · pdf · doi:10.3390/ijms18081699
openalex publication_date 2017/08/03 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30
Although its prevalence is declining, gastric cancer remains a significant public health issue. The bacterium Helicobacter pylori is known to colonize the human stomach and induce chronic atrophic gastritis, intestinal metaplasia, and gastric cancer. Results using a Mongolian gerbil model revealed that H. pylori infection increased the incidence of carcinogen-induced adenocarcinoma, whereas curative treatment of H. pylori significantly lowered cancer incidence. Furthermore, some epidemiological studies have shown that eradication of H. pylori reduces the development of metachronous cancer in humans. However, other reports have warned that human cases of atrophic metaplastic gastritis are already at risk for gastric cancer development, even after eradication of these bacteria. In this article, we discuss the effectiveness of H. pylori eradication and the morphological changes that occur in gastric dysplasia/cancer lesions. We further assess the control of gastric cancer using various chemopreventive agents.